{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q16473",
      "entity_text" : "Xa",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00910",
      "entity_text" : "FXa",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Apixaban and Rivaroxaban are two factor Xa (FXa) inhibitors approved for anticoagulation in the United States.6 Their rapid onset and offset make bridging therapy unnecessary which is a convenient peri-procedural option.14 In contrast to VKAs, FXa can potentially prevent de novo thrombi and resolve established ones by directly inhibiting free and thrombus associated FXa.",
  "reading_complete" : "2020-08-02T08:51:34Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:50:10Z",
  "trigger" : "prevent",
  "evidence" : [ "Xa (FXa) inhibitors approved for anticoagulation in the United States.6 Their rapid onset and offset make bridging therapy unnecessary which is a convenient peri-procedural option.14 In contrast to VKAs, FXa can potentially prevent" ],
  "pmc_id" : "6332814",
  "score" : 0
}